RAPID TREND SHIFT IN RADIOLOGY TECHNOLOGY AND ACCESSIBILITY
With
Dr Mansoor Parker,
Diagnostic & Interventional Radiologist & Founding Partner,
Quantum Radiology, Sydney &
Board Member,
Australian Diagnostic Imaging Association
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | October 2025
Dr Mansoor Parker obtained his medical degree from the University of Tasmania. He then completed his specialist radiology training at Nepean Hospital, Sydney with subspecialty interests in Interventional Radiology and Pain Management, Musculoskeletal, Cardiac and Abdominal Imaging. Dr Parker is a qualified specialist since 2005 and is a member of the Royal Australian and New Zealand College of Radiologists and the exclusive Australasian Musculoskeletal Imaging Group (AMSIG) as well as the Interventional Radiology Society of Australasia (IRSA).
Dr Parker has completed his Masters Training in Cardiac CT (Level B) and CT Colonography. He has also completed CT Colonography and Cardiac CT Angiography Accreditation obtaining Level 2 Society of Cardiovascular CT (CTCA), the highest level available in Australia. He sits on the board of directors of Australian Diagnostic Imaging Associated (ADIA) and is a committee member of the Medical Imaging Accreditation Scheme Advisory Committee (MIASAC) as part of the Australian Commission on Safety and Quality in Health Care.
Dr Mansoor Parker has been involved in developing CT Colonography software used on many CT machines today. Dr Parker is the founding partner of Quantum Radiology (founded in 2005) and serves in the position of the Chair of the Doctors Management Committee (DMC) at the Quantum Medscan Radiology Group
Source: Supplied
-
Jamie Stanistreet talks Medical Technology
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific -
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
